Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11,886 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inhibition of bone erosion, determined by high-resolution peripheral quantitative computed tomography (HR-pQCT), in rheumatoid arthritis patients receiving a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) plus denosumab vs csDMARD therapy alone: an open-label, randomized, parallel-group study.
Iwamoto N, Chiba K, Sato S, Shiraishi K, Watanabe K, Oki N, Okada A, Koga T, Kawashiri SY, Tamai M, Hosogaya N, Furuyama M, Kobayashi M, Saito K, Okubo N, Uetani M, Osaki M, Kawakami A. Iwamoto N, et al. Among authors: kobayashi m. Arthritis Res Ther. 2022 Dec 7;24(1):264. doi: 10.1186/s13075-022-02957-w. Arthritis Res Ther. 2022. PMID: 36476479 Free PMC article. Clinical Trial.
Comparative study of the inhibitory effect on bone erosion progression with denosumab treatment and conventional treatment in rheumatoid arthritis patients: study protocol for an open-label randomized controlled trial by HR-pQCT.
Iwamoto N, Sato S, Sumiyoshi R, Chiba K, Miyamoto N, Arinaga K, Kobayashi M, Yamamoto H, Osaki M, Kawakami A. Iwamoto N, et al. Among authors: kobayashi m. Trials. 2019 Aug 13;20(1):494. doi: 10.1186/s13063-019-3589-8. Trials. 2019. PMID: 31409388 Free PMC article.
Predictors of new bone erosion in rheumatoid arthritis patients receiving conventional synthetic disease-modifying antirheumatic drugs: Analysis of data from the DRIVE and DESIRABLE studies.
Takeuchi T, Soen S, Ishiguro N, Yamanaka H, Tanaka S, Kobayashi M, Okubo N, Nitta T, Tanaka Y. Takeuchi T, et al. Among authors: kobayashi m. Mod Rheumatol. 2021 Jan;31(1):34-41. doi: 10.1080/14397595.2019.1703484. Epub 2020 Jan 9. Mod Rheumatol. 2021. PMID: 31826682 Clinical Trial.
11,886 results
You have reached the last available page of results. Please see the User Guide for more information.